<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04503278</url>
  </required_header>
  <id_info>
    <org_study_id>BNT211-01</org_study_id>
    <secondary_id>2019-004323-20</secondary_id>
    <nct_id>NCT04503278</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX</brief_title>
  <official_title>Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech Cell &amp; Gene Therapies GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/IIa, FIH, open-label, multicenter, dose escalation trial with expansion&#xD;
      cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T/CLDN6 CAR-T(A) with or&#xD;
      without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid&#xD;
      tumors.&#xD;
&#xD;
      The trial started with CLDN6 RNA-LPX, a liposomal formulation comprising an unmodified RNA.&#xD;
      In order to optimize CAR-T cell persistence in patients, an alternative RNA-LPX, CLDN6&#xD;
      modRNA-LPX, will be tested once the RP2D dose for CLDN6 CAR-T(A) ± CLDN6 RNA-LPX is&#xD;
      identified.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">September 2037</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment-emergent adverse events (TEAEs) within a patient including ≥ Grade 3, serious, fatal TEAEs by relationship</measure>
    <time_frame>up to 25 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAEs</measure>
    <time_frame>up to 25 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicity (DLT) within a patient during the DLT evaluation period</measure>
    <time_frame>Day 1 to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the levels and kinetics of soluble immune factors measured by cytokine multiplex assay</measure>
    <time_frame>Baseline up to 25 months</time_frame>
    <description>Systemic effects in patients will be assessed (e.g., TNF, IFN-γ, IL-2, soluble IL-2Rα, IP-10, IL-12, IFN-α, IL-6, soluble IL-6R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors [RECIST 1.1]) is observed as best overall response</measure>
    <time_frame>up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after the first dose) is observed as best overall response</measure>
    <time_frame>up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (Progressive disease (PD) per RECIST 1.1/recurrence) or death from any cause, whichever occurs first</measure>
    <time_frame>up to 25 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 CLDN6 CAR-T/CLDN6 CAR-T(A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation in lymphodepleted patients until the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation until the MTD and/or RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLDN6 CAR-T/CLDN6 CAR-T(A)</intervention_name>
    <description>administered as an i.v. infusion.</description>
    <arm_group_label>Part 1 CLDN6 CAR-T/CLDN6 CAR-T(A)</arm_group_label>
    <arm_group_label>Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX</intervention_name>
    <description>administered as an i.v. injection at protocol-specified intervals.</description>
    <arm_group_label>Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Phase 1 of the trial&#xD;
&#xD;
          -  Each patient enrolled in the trial must have CLDN6-positive tumor regardless of tumor&#xD;
             histology defined as ≥ 50% of tumor cells expressing ≥ 2+ CLDN6 protein using a&#xD;
             semi-quantitative immunohistochemistry (IHC) assay in a central laboratory for&#xD;
             specific detection of CLDN6 protein expression in formalin-fixed, paraffin-embedded&#xD;
             (FFPE) neoplastic tissues.&#xD;
&#xD;
          -  Availability of a FFPE tumor tissue sample. FFPE can be from an archival tumor tissue&#xD;
             sample, and it should be from the most recent tumor tissue obtained. If this is not&#xD;
             available, patient must be biopsied for CLDN6 staining.&#xD;
&#xD;
          -  Must have histological documentation of the original primary tumor via a pathology&#xD;
             report.&#xD;
&#xD;
          -  Must have measurable disease per RECIST 1.1 (except for germ cell tumors, where&#xD;
             patients can be evaluated according to Cancer-Antigen (CA)-125, Alpha-fetoprotein&#xD;
             (AFP) or human chorionic gonadotropin (hCG) [as applicable] if they have a&#xD;
             pre-treatment sample that is at least twice the upper limit of normal).&#xD;
&#xD;
          -  Must have a histologically confirmed solid tumor that is metastatic or unresectable&#xD;
             and for which there is no available standard therapy likely to confer clinical&#xD;
             benefit, or patient who is not a candidate for such available therapy.&#xD;
&#xD;
          -  Must be ≥ 18 years of age at the time the pre-screening informed consent is signed.&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) indicating that he or she understands the&#xD;
             purpose of and procedures required for the trial and are willing to participate in the&#xD;
             trial prior to any trial-related assessments or procedures.&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group performance status of 0 to 1.&#xD;
&#xD;
          -  Must have adequate coagulation function at screening as defined in the protocol.&#xD;
&#xD;
          -  Must have adequate hematologic function at screening as defined in the protocol.&#xD;
&#xD;
          -  Must have adequate hepatic function at screening as defined in the protocol.&#xD;
&#xD;
          -  Must have adequate renal function at screening as defined in the protocol.&#xD;
&#xD;
          -  Must be able to attend trial visits as required by the protocol.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum (beta-human&#xD;
             chorionic gonadotropin) test/value at screening. Patients who are post-menopausal or&#xD;
             permanently sterilized can be considered as not having reproductive potential.&#xD;
&#xD;
          -  WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted&#xD;
             reproduction during the entire trial and thereafter.&#xD;
&#xD;
          -  WOCBP and men that are sexually active with a WOCBP and have not had a vasectomy must&#xD;
             agree to use highly effective birth control method(s), such as barrier method of birth&#xD;
             control, e.g., either condom with spermicidal foam/gel/film/cream/suppository for men;&#xD;
             and/or for females occlusive cap (diaphragm or cervical/vault caps) with spermicidal&#xD;
             foam/gel/film/cream/suppository; an intrauterine device; and/or hormone-based&#xD;
             contraception, with established use of oral, injected, or implanted hormonal methods&#xD;
             of contraception. True abstinence is an acceptable alternative to the use of&#xD;
             contraception.&#xD;
&#xD;
          -  Men must agree not to father a child or donate sperm, and WOCBP must agree not to&#xD;
             become pregnant during the trial and for at least 12 months after the CLDN6&#xD;
             CAR-T/CLDN6 CAR-T(A) infusion or CLDN6 (mod)RNA-LPX treatment.&#xD;
&#xD;
        For Part 2 only:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor fulfilling inclusion criteria&#xD;
             1-4 that is metastatic or unresectable, and for whom there is no available standard&#xD;
             therapy likely to confer clinical benefit, or patient who is not a candidate for such&#xD;
             available therapy.&#xD;
&#xD;
        Exclusion Criteria: Phase 1 of the trial&#xD;
&#xD;
          -  Has received prior CAR-T therapy, except CLDN6 CAR-T/CLDN6 CAR-T(A) therapy.&#xD;
&#xD;
          -  Has received vaccination with live virus vaccines within 6 weeks prior to the start of&#xD;
             lymphodepletion (LD).&#xD;
&#xD;
          -  Receives concurrent systemic (oral or i.v.) steroid therapy &gt; 10 mg prednisolone&#xD;
             daily, or its equivalent, for an underlying condition.&#xD;
&#xD;
          -  Has side effects of any prior therapy or procedures for any medical condition not&#xD;
             recovered to national cancer institute (NCI) common terminology criteria for adverse&#xD;
             events (CTCAE v.5) Grade ≤ 1.&#xD;
&#xD;
        Medical conditions:&#xD;
&#xD;
          -  Current evidence of new or growing brain or spinal metastases during screening.&#xD;
             Patients with known brain or spinal metastases may be eligible if they:&#xD;
&#xD;
               1. Have had radiotherapy or another appropriate therapy for the brain or spinal&#xD;
                  metastases,&#xD;
&#xD;
               2. Have no neurological symptoms,&#xD;
&#xD;
               3. Have stable brain or spinal disease on the computer tomography (CT) or magnetic&#xD;
                  resonance imaging (MRI) scan within 4 weeks before signing of the ICF,&#xD;
&#xD;
               4. Are not undergoing acute corticosteroid therapy or steroid taper. Chronic steroid&#xD;
                  therapy is acceptable provided that the dose is stable for the last 14 days prior&#xD;
                  to screening (≤ 10 mg prednisolone daily or equivalent),&#xD;
&#xD;
               5. Do not require steroid therapy within 7 days before the first dose of CLDN6&#xD;
                  CAR-T/CLDN6 CAR-T(A),&#xD;
&#xD;
               6. Have anticipated imminent fracture or cord compression due to spinal bone&#xD;
                  metastases.&#xD;
&#xD;
          -  Has history of epilepsy. Isolated seizures in the past or febrile seizures in&#xD;
             childhood are permitted; has a history of a cerebrovascular accident or transient&#xD;
             ischemic attack less than 6 months ago.&#xD;
&#xD;
          -  Pericardial effusion requiring any drainage is excluded.&#xD;
&#xD;
          -  Has an active autoimmune disease including but not limited to inflammatory bowel&#xD;
             disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or&#xD;
             multiple sclerosis. Has any active immunologic disorder requiring immunosuppression&#xD;
             with steroids or other immunosuppressive agents with the exception of patients with&#xD;
             isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled&#xD;
             hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's&#xD;
             disease. Patients with controlled hyperthyroidism must be negative for thyroglobulin,&#xD;
             thyroid peroxidase antibodies, and thyroid-stimulating immunoglobulin prior to trial&#xD;
             drug administration.&#xD;
&#xD;
          -  Seropositivity for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Known history/positive serology for hepatitis B requiring active antiviral therapy&#xD;
             (unless immune due to vaccination or resolved natural infection or unless passive&#xD;
             immunization due to immunoglobulin therapy). Patients with positive serology must have&#xD;
             hepatitis B virus viral load below the limit of quantification.&#xD;
&#xD;
          -  Active hepatitis C virus (HCV) infection; patients who have completed curative&#xD;
             antiviral treatment with HCV viral load below the limit of quantification are allowed.&#xD;
&#xD;
          -  Has a known hypersensitivity to a component of CLDN6 CAR-T/CLDN6 CAR-T(A) or CLDN6&#xD;
             (mod)RNA-LPX cancer vaccine drug product, or another similar compound.&#xD;
&#xD;
          -  Only for patients recruited for Part 2 with LD chemotherapy (CLDN6 CAR-T/CLDN6&#xD;
             CAR-T(A) + CLDN6 (mod)RNA-LPX with LD chemotherapy): history of severe immediate&#xD;
             hypersensitivity reaction to LD chemotherapy consisting of cyclophosphamide or&#xD;
             fludarabine.&#xD;
&#xD;
          -  Has a history of another primary cancer within the 2 years prior to enrollment except&#xD;
             for the following: Non-melanoma skin cancer, cervical carcinoma in situ, superficial&#xD;
             bladder cancer, prostate cancer with currently undetectable prostate specific antigen,&#xD;
             or other non-metastatic carcinoma that has been in complete remission without&#xD;
             treatment for more than 2 years.&#xD;
&#xD;
          -  Receipt of allogenic stem cell transplantation in the 5 years prior to enrollment into&#xD;
             the trial.&#xD;
&#xD;
          -  Patients with acute or chronic graft versus host disease.&#xD;
&#xD;
        Other comorbidities:&#xD;
&#xD;
          -  Has abnormal electrocardiograms (ECGs) that are clinically significant, such as QT&#xD;
             prolongation.&#xD;
&#xD;
          -  In the opinion of the Investigator, has any concurrent conditions that could pose an&#xD;
             undue medical hazard or interfere with the interpretation of the trial results; these&#xD;
             conditions include, but are not limited to:&#xD;
&#xD;
               1. Ongoing or active infection requiring antibiotic/antiviral/antifungal therapy&#xD;
&#xD;
               2. Concurrent congestive heart failure (New York Heart Association Functional&#xD;
                  Classification Class III or IV)&#xD;
&#xD;
               3. Concurrent unstable angina&#xD;
&#xD;
               4. Concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial&#xD;
                  fibrillation)&#xD;
&#xD;
               5. Acute coronary syndrome within the previous 6 months&#xD;
&#xD;
               6. Significant pulmonary disease (shortness of breath at rest or on mild exertion)&#xD;
                  for example due concurrent severe obstructive pulmonary disease.&#xD;
&#xD;
          -  Has a cognitive, psychological or psychosocial impediment that would impair the&#xD;
             ability of the patient to receive therapy according to the protocol or adversely&#xD;
             affect the ability of the patient to comply with the informed consent process,&#xD;
             protocol, or protocol-required visits and procedures.&#xD;
&#xD;
          -  Is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BioNTech Responsible Person</last_name>
    <role>Study Director</role>
    <affiliation>BioNTech SE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioNTech clinical trials patient information</last_name>
    <phone>+49 6131 9084</phone>
    <phone_ext>0</phone_ext>
    <email>patients@biontech.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen - Hämatologie &amp; Intrinsische Onkologie - Medizinische Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf - II Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover - Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln AÖR-Centrum für Integrierte Onkologie (CIO)-Studienzentrum der Klinik I für Innere Medizin (CTU Cologne)</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz - III Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg - Klinik und Poliklinik für Innere Medizin III</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>He Nederlands Kanker Instituut (The Netherlands Cancer Institute) - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Universitair Medisch Centrum - Medical oncology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Comprehensive Cancer Center Cancerstudieenheten Huddinge Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>September 15, 2023</last_update_submitted>
  <last_update_submitted_qc>September 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLDN6-positive relapsed or refractory advanced solid tumors</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04503278
org study id: BNT211-01
secondary id: 2019-004323-20
nct id: NCT04503278
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a Phase I/IIa, FIH, open-label, multicenter, dose escalation trial with expansion
      cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T/CLDN6 CAR-T(A) with or
      without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid
      tumors.

      The trial started with CLDN6 RNA-LPX, a liposomal formulation comprising an unmodified RNA.
      In order to optimize CAR-T cell persistence in patients, an alternative RNA-LPX, CLDN6
      modRNA-LPX, will be tested once the RP2D dose for CLDN6 CAR-T(A) ± CLDN6 RNA-LPX is
      identified.
allocation: Non-Randomized
intervention model: Factorial Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Occurrence of treatment-emergent adverse events (TEAEs) within a patient including ≥ Grade 3, serious, fatal TEAEs by relationship
time frame: up to 25 months
measure: Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAEs
time frame: up to 25 months
measure: Occurrence of dose-limiting toxicity (DLT) within a patient during the DLT evaluation period
time frame: Day 1 to day 28
measure: Change from baseline in the levels and kinetics of soluble immune factors measured by cytokine multiplex assay
time frame: Baseline up to 25 months
description: Systemic effects in patients will be assessed (e.g., TNF, IFN-γ, IL-2, soluble IL-2Rα, IP-10, IL-12, IFN-α, IL-6, soluble IL-6R).
measure: Objective response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors [RECIST 1.1]) is observed as best overall response
time frame: up to 25 months
measure: Disease control rate (DCR) defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after the first dose) is observed as best overall response
time frame: up to 25 months
measure: Duration of response (DOR) defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (Progressive disease (PD) per RECIST 1.1/recurrence) or death from any cause, whichever occurs first
time frame: up to 25 months
arm group label: Part 1 CLDN6 CAR-T/CLDN6 CAR-T(A)
arm group type: Experimental
description: Dose escalation in lymphodepleted patients until the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
arm group label: Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX
arm group type: Experimental
description: Dose escalation until the MTD and/or RP2D.
intervention type: Biological
intervention name: CLDN6 CAR-T/CLDN6 CAR-T(A)
description: administered as an i.v. infusion.
arm group label: Part 1 CLDN6 CAR-T/CLDN6 CAR-T(A)
arm group label: Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX
intervention type: Biological
intervention name: CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX
description: administered as an i.v. injection at protocol-specified intervals.
arm group label: Part 2 Vaccine-modulated - CLDN6 unmodified RNA-LPX/CLDN6 modified RNA-LPX
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: BioNTech Responsible Person
role: Study Director
affiliation: BioNTech SE
last name: BioNTech clinical trials patient information
phone: +49 6131 9084
phone ext: 0
email: patients@biontech.de
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
country: Australia
country: Germany
country: Netherlands
country: Sweden
responsible party type: Sponsor
sharing ipd: No